Skip to content

Search

Food and nutrition

Discover essential insights on food and nutrition for Type 1 Diabetes, from carb counting to meal planning.

Pump Comparison tool

Pump Comparison tool . This easy-to-use updated comparison tool is designed to help you pick the right device for your family.

Be involved

Find out how to participate in our research and community groups.

Clinical Trials

We are in a new era of T1D care. We can now identify and provide care for people across a spectrum of T1D, from early-stage T1D to symptomatic insulin requiring T1D (Stage 3 and Stage 4). And for the first time since the discovery of insulin over 100 years ago, Australia has approved a new therapy, Teplizumab.

A community-led, trauma-informed psychosocial intervention to improve health outcomes of children and young people with Type-1 diabetes

T1D can be a traumatic diagnosis for children and young people, and often involves strict adherence to painful treatments, comorbid mental health conditions, and shortened life expectancy.

DiabHQ

The DiabHQ Patient Portal app is now available to WA children and families living with Type 1 diabetes.

Child health research made possible through Telethon’s support

The generous support of Western Australians through Channel 7’s Telethon is helping to fund life-changing child health research, with two The Kids Research Institute Australia researchers awarded significant grants.

Six months of hybrid closed-loop therapy improves diabetes-specific positive well-being, and reduces diabetes distress and fear of hypoglycemia: secondary analysis of a controlled trial

This analysis aimed to investigate diabetes-specific psychological outcomes among adults with type 1 diabetes (T1D) using hybrid closed-loop (HCL) versus standard therapy. 

"i Think i Could Have Used It Better": Experiences of Youth with High HbA1c Commencing Advanced Hybrid Closed-Loop Therapy in a Clinical Trial Setting - A Qualitative Research

Advanced hybrid closed-loop (AHCL) therapy improves glycemia. However, it is not known if there is an improvement in overall outcomes with AHCL for youth with type 1 diabetes (T1D) at high risk of diabetes-related complications. The study aimed to capture the experiences of youth with suboptimal glycemic control when commencing AHCL therapy in a clinical trial setting.